Generation Bio to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Generation Bio (Nasdaq: GBIO), a leader in non-viral gene therapy, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 12, 2020, at 10:20 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Generation Bio (Nasdaq: GBIO), a leader in non-viral gene therapy, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 12, 2020, at 10:20 a.m. ET. The presentation will highlight their innovative platforms, featuring closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP), aimed at providing long-lasting therapies for both rare and prevalent diseases. A live webcast will be accessible on their investor website, with an archive available for 60 days post-event.
Details
News Market Reaction – GBIO
The recorded move for GBIO in the trading session of this news was +2.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced that management will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, Aug. 12, 2020 at 10:20 a.m. ET.
A live webcast of the company presentation will be available in the investor section of the company's website at www.generationbio.com. The webcast will be archived for 60 days following the presentation.
About Generation Bio
Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.
For more information, please visit www.generationbio.com.
Contact:
Investors
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com
910-777-3049
Media
Stephanie Simon
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.